B. Braun Medical has announced that Jean-Claude Dubacher will succeed longtime company leader Carroll Neubauer as chairman and CEO on Jan. 1, 2020.
Neubauer will stay on as chairman and CEO of B. Braun of America, which owns B. Braun Medical (Bethlehem, Pa.), admixture pharmaceutical firm CAPS, Aesculap and B.Braun Interventional Systems. He has been chair and CEO of B. Braun Medical since 1997.
Dubacher joined B. Braun August 1 as president of B. Braun Medical. He has more than 15 years in healthcare consulting and corporate roles, including strategy, commercial, supply chain and manufacturing, according to the company. Before joining B. Braun, Dubacher led commercial operations for Johnson & Johnson’s (NYSE:JNJ) surgical ophthalmology division in Europe, the Middle East and Africa. Mr. Dubacher holds a Ph.D. in law from the University of Zurich in Switzerland, and an MBA from Harvard University Business School.
B. Braun Medical is made up of four divisions: hospital care, outpatient markets, renal therapies and original equipment manufacturing. Its IV therapy products include IV solutions, drug-delivery systems, vascular access devices (standard and needle-free IV systems and IV safety catheters) and infusion pumps. The company also manufactures, markets, distributes and supports a medical product line that includes advanced products for pharmacy, clinical nutrition, anesthesia/pain control, hemodialysis and renal replacement therapy.
B. Braun spokeswoman Allison Longenhagen told MassDevice that the leadership transition was planned, but declined to say how long it had been in the works.
B. Braun Medical posted 2018 sales of $1.916 billion in the U.S. and and € 6.908 billion worldwide, Longenhagen said. Parent company, Germany-based B. Braun Menslungen, ranks in the top 20 of Medical Design & Outsourcing’s Big 100 medical device companies.